Background: Randomised trials have shown that salt reduction lowers blood pressure (BP). However, most previous trials were in whites, fewer in blacks and none in Asians. Methods: 71 whites, 69 blacks and 29 Asians with untreated mildly raised BP completed a randomised double-blind crossover trial of salt restriction with Slow-Sodium (Slow-Na) or placebo, each for 6 weeks. Results: Mean±s.d.
42 patients with essential hypertension, aged 35-74 (median 59), 30 male, 12 female, participated in a double-blind, cross-over study. They received, in random order, 4 weeks of once-daily treatment with each of bendroflumethiazide (BFZ) 5-10 mg, atenolol 50-100 mg, combination (BFZ 2.5-5 mg þ atenolol 25-50 mg) and placebo. Each active treatment was force-titrated at 2 weeks and separated by a 4-week placebo washout. At each visit, we measured BP and plasma electrolytes, and a 75 g OGTT was performed. Data (shown as mean (s.d.)) was analysed by repeated measures, within and between drugs. Only BFZ increased the 2-h glucose, by 11%, P ¼ 0.006 (4 vs 0 weeks), 0.013 (BFZ vs placebo). There was no change in 30-min insulin.
Short-term dosing with high-dose thiazide allows significant impairment of glucose tolerance to be detected after just 4 weeks. This should help investigation of the pathogenesis of thiazideinduced diabetes. Unlike the clearly synergistic effect of combination on BP, there was no change in the OGTT, due perhaps to the protective effect of better BP control. The interesting question now is whether, using this methodology, we can show Ksparing diuretics to be superior to thiazides in their influence on glucose tolerance.
PA.03. Gender differences in the cross-sectional relationships between sleep duration, interleukin-6 and high-sensitivity C-reactive protein: the Whitehall II study Background: Emerging evidence suggests that sleep disturbances play a role in the morbidity of chronic conditions, including the development of hypertension and cardiovascular disease for which an underlying inflammatory component has been proposed.
Methods and results:
The relationships between sleep duration and two markers of inflammation, interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) were examined in white-collar British civil servants (all white individuals) from the Whitehall II study (n ¼ 4642 for IL-6; n ¼ 4677 for hs-CRP). Following multiple adjustments for demographic characteristics and cardiovascular risk factors including blood pressure there were no overall linear or non-linear trends between sleep duration and IL-6. However, in women but not men (interaction Po0.05), levels of IL-6 were consistently lower in individuals who slept 8 h (11% ) as compared to 7 h (P ¼ 0.05). With hs-CRP there was no association between hs-CRP and sleep duration in men. However, there was a significant non-linear U-shaped association in women, the level of hs-CRP being significantly higher in short sleepers after multiple adjustments (P ¼ 0.04) (interaction Po0.05). Conclusions: No significant variation in inflammatory markers with sleep duration was observed in men. By contrast, both IL-6 and hs-CRP levels vary with sleep duration in women. The observed pattern of variation was different according to the inflammatory marker observed. Further longitudinal studies are required to see if there is a temporal relationship between short sleep and markers of inflammation to support causality. Objective: The aim of the study was to assess whether lowering systolic blood pressure already in the normal range by approximately 10 mm Hg would lead to a reduction in LVH. Methodology: Fifty-one normotensive subjects with echocardiographic LVH were randomly assigned to an active treatment arm (extra antihyperensive medication); or placebo in a ratio of 2:1. Cardiac magnetic resonance imaging (CMR) was used to establish changes in left ventricular mass index (LVMI) over the 12 months' study period. Thirty-five subjects completed the study (active 23: placebo 12).
Results: Average baseline systolic blood pressure was 122.10 mm Hg in the active group and 123.83 mm Hg in the placebo group (P ¼ 0.646). The mean baseline CMR LVMI was 59.16 g/m 2 in the placebo group and 65.88 g/m 2 in the active group (P ¼ 0.114). The mean difference between baseline and end of study blood pressure was À9.33 mm Hg in the active group and À0.08 mm Hg in the placebo group (P ¼ 0.007). This is a much greater BP fall than, for example, the HOT study. Introduction: Aspirin is the most commonly used anti-platelet drug in the secondary prevention of ischaemic stroke. Biochemical aspirin resistance may be defined as failure of aspirin to inhibit platelet thromboxane A 2 production, whereas clinical aspirin resistance is diagnosed following the occurrence of an atherothrombotic event in patients receiving a therapeutic dose of aspirin. We determined the prevalence and nature of aspirin resistance in 44 adults admitted with a diagnosis of suspected ischaemic stroke. Methods: On admission to the stroke unit, platelet function was measured by optical aggregometry in platelet-rich plasma, after stimulation with arachidonic acid (AA), ADP and collagen. Urinary 11-dehydro-thromboxane B2 metabolite was measured by immunoassay. Platelet function was tested again 24 h after administration of 150 mg aspirin on the ward.
Results: Residual AA-stimulated platelet aggregation (X10% aggregation) indicating a poor response to aspirin was foundin 18 patients (41%). Of these, 10 remained poorly responsive after aspirin dosing in hospital, suggesting causes other than poor compliance in 23% of patients. In vitro, platelet aggregation could be inhibited further by addition of acetylsalicylic acid in only 3 of these subjects, indicating true biochemical aspirin resistance in 16%. Urinary 11-dehydro-TxB2 was not significantly different between good and poor responders to aspirin (median (iqr) 77.0 (38.9-156.8) vs 86.2 (50.0-261.2) ng/mmol of creatinine) and therefore may not be a good marker of impaired platelet response to aspirin. Conclusions: These data suggest that biochemical aspirin resistance and poor compliance with therapy contribute to failure of aspirin in a significant proportion of patients with acute stroke.
PB.05. Superoxide release by whole blood and mononuclear cells as markers of oxidative stress in patients with coronary artery disease MU Moreno Zulategui, JA Dymott, C Taurino, GA Berg, JP Rocchiccioli, C Delles and AF Dominiczak BHF Glasgow Cardiovascular Research Centre, Glasgow, UK Reactive oxygen species are a key factor in the development of coronary artery disease (CAD). Superoxide anion (SO) release by mononuclear cells (MC) and whole blood (WB) contributes significantly to vascular and systemic oxidative stress in CAD. We analysed SO levels in WB and MC in 50 patients undergoing elective coronary artery bypass graft (CABG) surgery (aged 68±2 years) and 14 controls (aged 69 ± 2 years). Furthermore, we analysed 24 patients post-CABG surgery, before and after a 3-month cardiac rehabilitation programme. SO was detected by electron paramagnetic resonance spectroscopy. MC were analysed in basal conditions and after stimulation with PMA to evaluate maximum SO release. Both basal SO release (48 ± 4 vs 31 ± 5 AU/min, P ¼ 0.012) and maximum SO release (505 ± 4 vs 187±3 AU/min, Po0.001) by MC were higher in patients than in controls. There was a correlation between SO release from WB and MC [R 2 ¼ 0.833, Po0.001]. The cardiac rehabilitation programme did not modify blood pressure, body mass index or white cell count but reduced MC maximum SO release (752 ± 0 vs 526 ± 7 AU/min, P ¼ 0.029) and whole blood SO generation (44±5 vs 31 ± 4 Â 10 3 AU/min, P ¼ 0.003), not modifying MC basal SO generation. We identified, for the first time, the correlation between systemic SO levels and MC SO release. Our results indicate that the cardiac rehabilitation programme after CABG surgery improves the oxidative stress status. We propose that SO determination in MC and WB may be a tool for assessing oxidative stress in patients with CAD.
PC.01. What do GPs do with the results of ambulatory blood pressure monitoring? N McGowan and PL Padfield
Western General Hospital, Edinburgh, UK Methods: We retrospectively identified 400 untreated, newly diagnosed, hypertensive patients (awake average X145/95 mm Hg) from our direct access ABPM database, divided equally pre and post GMS contract implementation (contract target p150/90 mm Hg) and recorded subsequent management in primary care. Results: After 12 months 75% of patients only were on antihypertensive therapy with no difference pre and post contract. Of those treated 60% achieved a BPp150/90 mm Hg pre contract (66% post contract) with only 17% reaching a 'guideline' target of o140/ 90 mm Hg pre contract (39% post contract)-Po0.001. Most treated patients (56% pre and 60% post contract) remained on a single antihypertensive agent. Office BP fall at one year was greater post contract-6/4 vs 12/6 mm Hg, Po0.001.
QOF data for the practices involved in the study quote BP p150/90 mm Hg in 78% of patients i.e., a 12% discrepancy. Conclusion: Despite confirmation of hypertension by ABPM 25% of patients were left untreated. The rate of blood pressure control in those commenced on therapy was substantially less than the average GP population with little evidence of treatment escalation and only a minor impact of incentivisation. It seems likely that patients for whom GPs request an ABPM are atypical of their general hypertensive population and may be less inclined to accept therapy. It is arguable however whether GPs use ABPM appropriately given their apparent rejection of the results.
PC.02. A novel method to derive central aortic systolic pressure (CASP) from the radial artery pressure waveform: validation with data from the CAFE study Background: Despite the large variation in pulse pressure waveform throughout the aorta, the diastolic decay of the pressure waveform is almost identical. We hypothesise that this is because there is a common reservoir pressure along the entire aorta, principally determined by the highly elastic proximal aortic root. We apply a new technique to calculate this reservoir pressure along the aorta to test this hypothesis. Method and Results: Using intra-arterial wires, pressure and Doppler velocity were measured at 10 cm intervals along the aorta in 16 patients (aged 55 ± 11 years). Pressure was separated into reservoir and wave components using the new wave-reservoir technique. In all patients, the intra-subject reservoir pressure waveforms were almost identical (mean correlation coefficient 0.99±0.01) regardless of the marked changes in the measured pressure waveform (systolic pressure P ¼ 0.020 and pulse pressure P ¼ 0.001). Significant variation in reservoir pressure was seen between subjects (peak reservoir ¼ 63.4-21.4 mm Hg). The reservoir pressure was the predominate determinant of the pressure waveform and accounted for 67.0±8.8% of the total integrated pulse pressure across all aortic sites.
Conclusions:
The aortic pressure waveform is predominately determined by the reservoir pressure. This reservoir pressure is similar along the length of the aorta despite marked changes in the shape of the measured pressure waveform. Manipulation of the arterial reservoir, rather than wave-reflection sites may be more important in regulation of blood pressure control. Impaired glucose tolerance (IGT) precedes diabetes and is associated with increased cardiovascular risk. Structural and functional abnormalities in the microvasculature often predate the earliest stages of the cardiovascular disease process. The ocular microcirculation in particular represents a preferential target for many disease processes. We aim to identify abnormalities in ocular blood flow using a novel technique, which may represent microvascular dysfunction in impaired glucose tolerance. Methods: Doppler ultrasound flow velocity recordings of the central retinal artery (CRA) and ophthalmic artery (OA) were carried out in 40 IGT patients and compared with 25 controls. The wavelet transform technique (1) was employed to analyse the waveforms in the frequency domain and the resistive index (RI) was calculated from peak systolic and end-diastolic velocities.
Results: In the CRA there was a significantly different mean spectral amplitude content between the two groups in frequency band 4 (IGT mean 6.94±1.23 versus control mean 6.10 ± 1.37; Po0.05). This difference was also apparent in frequency band 4 of the OA (IGT mean 6.44±1.39 versus control mean 5.71 ± 1.21; Po0.05). RI was not significantly different between the two groups in either artery. Conclusions: In patients who have not yet developed diabetes, there are characteristic abnormalities in ocular blood flow which are detected using wavelet transform, but not identified using the more traditional RI. This may be a useful way to predict cardiovascular disease in this patient group. University of Glasgow, Glasgow, UK Objective: We previously identified blood pressure quantitative trait loci (QTL) mapping to rat chromosomes 2 and 3 in an F2 cross derived from SHRSP and WKY strains. We also identified significant interaction between loci on chromosomes 2 and 3 using Pseudomarker (v0.9) statistical framework. The aim of this study was to generate a double congenic strain to confirm chromosome 3 QTL and investigate the interaction between loci on the implicated chromosomes. Methods: A marker-assisted breeding strategy was used to generate SP.WKYGla2a/3a double congenic strain (D2Rat13-D2Rat157, D3Mgh16-D3Wox28), using SHRSP as recipient and WKY as the donor strain. Haemodynamic measurements were carried out using radiotelemetry during baseline and saltloaded periods. Microarray expression profiles comparing salt-loaded SHRSP and WKY kidneys were analysed by Ingenuity Pathway Analysis (IPA). Results: Systolic blood pressure was significantly reduced in the SP.WKYGa2a/3a strain (166.8 ± 4.6 mm Hg, n ¼ 7) compared to SHRSP (258.1 ± 6.1 mm Hg, n ¼ 13) (P ¼ 0.0001, F ¼ 97.77, repeated measures ANOVA). Pulse pressure was also significantly reduced compared to SHRSP (49.4 ± 1.6 vs 69.1 ± 3.1 mm Hg, P ¼ 0.0001, F ¼ 34.17) and achieved levels comparable to WKY (45.3± 1.9 mm Hg, n ¼ 10). Pulse pressure diurnal variation observed in SHRSP during salt-loading was abolished in the double congenic strain (AUC; P ¼ 0.0001, F ¼ 13.56). IPA identified a cluster of transcription factors (PHTF1, FUBP3, PBX3, CEBPD, DNAJB6) located within the implicated congenic intervals, underling inflammation, cellular growth, proliferation and cell death functional networks. Conclusions: Almost complete reversal of SHRSP hypertensive haemodynamic profiles has been achieved in the SP.WKYGla2a/3a congenic strain. This strain will allow interrogation of complex genegene, gene-environment interactions contributing to salt-sensitive hypertension in the SHRSP. Objective: To utilise congenic strains and microarray gene expression profiling during the development of hypertension to identify candidate genes and pathophysiological pathways underlying oxidative stress and hypertension in young SHRSP. Methods: Renal microarray profiles were compared with Affymetrix RGU34 genome chips from 5 week old SHRSP, WKY and the SP.WKYGla2c* (2c*) congenic strain containing Gstm1, a previously identified positional candidate gene for hypertension. Significant differential expression was determined by Rank Products (false discovery rate (FDR) of 5%) and analysed with Ingenuity Pathway Analysis. Superoxide was measured in whole kidney homogenates and glutathione (GSH) levels measured and analysed with ANOVA or T-test. Results: Renal SHRSP, 2c* and WKY expression profiles were compared identifying significantly differentially expressed genes involved in glutathione metabolism including Gstm1 (2c* vs SHRSP, FDR ¼ 0.0, FC ¼ 9.4, WKY vs SHRSP FDR ¼ 0.0, FC ¼ 7.5) and solute carrier 7, member12-like (Slc7a12-like) (2c* vs SHRSP, FDR ¼ 0.0, FC ¼ À2.9, WKY vs SHRSP, FDR ¼ 0.0, FC ¼ À2.3). Differential expression was confirmed by qRT-PCR and sequence analysis identified single nucleotide polymorphisms in the promoters. There was a significant increase in NADH stimulated superoxide levels in the SHRSP compared to 2c* and WKY (SHRSP 10.8 ± 1.3, 2c* 8.5±1.1, WKY 8.3±0.9 mmoles/min/mg protein F ¼ 6.5, P ¼ 0.016) and GSH levels were significantly increased in WKY (SHRSP 18.3 ± 3.4, 2c* 15.4 ± 2.7, WKY 29.1±5.0 mmoles/mg protein F ¼ 20.9, Po0.001). At 16 week of age there was a significant increase in GSH levels only in the 2c* strain (5 week 15.4 ± 2.7 vs 16 week 20.5 ± 1.6 P ¼ 0.006). Conclusion: These findings identify significantly regulated genes and disrupted pathways affecting oxidative stress and glutathione metabolism in the SHRSP during the development of hypertension. University of Glasgow, Glasgow, UK Background: Glutathione s-transferase mu-type 1 (Gstm1) has previously been identified as a positional and functional candidate gene for hypertension in the stroke prone spontaneously hypertensive rat (SHRSP). At present, there are no selective pharmacological inhibitors of Gstm1, making further investigation of its function difficult. To overcome this, an approach involving both RNA interference via short interfering RNA (siRNA) and vector driven expression of Gstm1 has been used. Methods: Specific siRNA sequences against Gstm1 were tested in a rat kidney tubular epithelial cell line (NRK52E). Cells were transfected with 30-100 nM siRNA. After 48 h, knock-down of Gstm1 protein and mRNA was determined by western blot and qRT-PCR. In addition to this, adenovirus vectors were generated to over-express Gstm1. LacZ expressing adenoviral vectors (Ad19pHTT) specifically designed to target renal tubular cells were generated and tested in the SHRSP. LacZ expression was determined by immunohistochemistry. Results: Gstm1 mRNA expression was significantly reduced, up to 85% (n ¼ 6, Po0.01). Gstm1 protein levels were also reduced compared to controls. Over-expression of Gstm1 resulted in a 2-fold increase in total glutathione transferase activity (n ¼ 3, Po0.01). Ad19pHTT infusion of SHRSP resulted in localised expression of LacZ within the tubular epithelium of the kidney. Conclusions: The techniques used in this study have resulted in successful modulation of Gstm1 expression in vitro. The integration of targeted vectors and modulation of Gstm1 expression will allow the role of Gstm1 to be investigated more fully in vivo. This system can also be applied to evaluate other candidate genes in hypertension.
PD.02. Metabolic phenotypes in SHRSP and

PD.04. Evaluation of a targeted delivery platform for in vivo modulation of Gstm1 expression
PD.05. The anorexigenic peptides, neuromedin U-25 and neuromedin S, are present in the human cardiovascular system and function as potent vasoconstrictors JD Mitchell, RE Kuc, JJ Maguire and AP Davenport University of Cambridge, Cambridge, UK Neuromedin U (NMU), shown to elicit a pressor response in rats (Minamino et al., 1985) , was paired with the 'orphan' G-protein-coupled receptors, NMU1 and NMU2 (Howard et al., 2000) . This peptide has an important role in energy regulation; NMU À/À mice developed obesity (Hanada et al., 2004) and NMU Arg165Trp variant co-segregated with childhood obesity (Hainerova et al., 2006) . Recently, neuromedin S (NMS) was paired with the same receptors and also has pressor (Mori et al., 2005) and anorexigenic actions (Ida et al., 2005) in rats. However, little is known about direct effects of these peptides on vascular beds and on their vascular effects in humans. Using a novel RIA, NMU-25-LI was detected in human plasma, left ventricle (LV), coronary artery (CA), saphenous vein (SV) and adipose tissue. HPLC established both NMU-25 and NMS were present in LV. Receptor autoradiography, using [
125 I]-NMU-25, demonstrated binding to myocardium of LV and medial smooth muscle layer of small and large diameter blood vessels. [
125 I]-NMU-25 showed saturable, specific and high affinity binding. In accordance with binding distribution, we have shown NMU-25 to be a potent vasoconstrictor of artery and vein in vitro. In CA, NMU-25 caused vasoconstriction with potency and maximum contractile response similar to angiotensin II. NMS constricted SV with similar potency to NMU-25 but a significantly lower maximum response, whereas NMU-25 (Arg165Trp) was without effect. Identification of specific binding sites, presence of endogenous peptide and discovery of function fulfil criteria for NMU-25 as an emerging transmitter in the human cardiovascular system.
PD.06. Improved left ventricular function in a hypertensive congenic strain K Gilday, D Graham and AF Dominiczak
University of Glasgow, Glasgow, UK Objective: We previously identified a QTL for left ventricular mass index (LVMI) on rat chromosome 14 in an F2 cross between SHRSP and WKY, which was confirmed by generation of the SP.WKYGla14a congenic strain. This study aimed to identify candidate genes and evaluate left ventricular (LV) function in SP.WKYGla14a. Methods: 16-week old male SHRSP (n ¼ 7) and SP.WKYGla14a (n ¼ 6) were imaged by echocardiography; LVMI (mg/g), relative wall thickness (RWT), ejection fraction (EF%), fractional shortening (FS%) were calculated from m-mode images. LV diastolic function was assessed using pulse wave Doppler. Vector velocity imaging (VVI) determined end systole (SR s ), end diastole (SR d ) strain rate and time to peak (TPk). Positional genes were identified by comparative mapping and analysed qRT-PCR in SHRSP and WKY whole heart. Results: LVMI and RWT were reduced in SP.WKYGla14a (2.7 Â 10-3, Po0.006; 0.48 ± 0.03, Po0.0002, respectively) versus SHRSP (3.0 Â 10 À3 , 0.61±0.04 respectively). E/A ratio was significantly reduced in SHRSP (1. Adjusting for age, weight, Townsend's index (measure of social deprivation), ethnicity, smoking history, alcohol consumption, fasting glucose, serum cholesterol, triglycerides and serum C-reactive protein, the independent influence of the adipokines on blood pressure were as follows:
Conclusion: Three adipokines were independently associated with SBP and DBP at this age. The proinflammatory adipokines had more influence on both BP measures independent of the women's body weight, other risk factors and inflammatory state measured by C-reactive protein. The mechanisms whereby dietary salt intake regulates blood pressure (BP) are not clear. Physiological increases in sodium in plasma or tissue culture are known to stimulate thirst and thereby fluid retention but also activate the local hypothalamic RAS, cellular changes in arterial smooth muscle and cardiac myocytes as well as endothelial stiffness. Large changes in salt intake alter plasma sodium but the effects of smaller changes are not known. We therefore studied the effect in 10 normotensive subjects in a randomised crossover study of 400 mls of soup with either 6 gms of salt or no added salt. Venous and arterialised blood samples and systolic and diastolic blood pressure were taken at baseline and at 30 min intervals for 4 h. Results: Salt soup increases, at its maximum, venous sodium by 3.13 ± 0.75 mmol/l, osmolality ) in each phase over 4 h. Gas chromatography was used to measure plasma concentrations of 8-epi-prostaglandin-F 2a , a marker of oxidative stress (n ¼ 10). Cardiac output (CO) and systemic vascular resistance (SVR) were measured by rebreathing of soluble and inert gas tracers (Innocor, Innovision). The forearm blood flow response to brachial artery infusions of the NO synthase inhibitor N G -monomethyl-L-arginine (L-NMMA, 2, 4 and 8 mmol min À1 , n ¼ 10) was used to assess basal NO availability. Exercise blood pressure was measured during low work load bicycle ergometry (50-100 Watts, n ¼ 10). Plasma isoprostanes increased after intralipid compared to the change after saline (26.8 ± 25.0 vs À29.3 ± 39.0 pg/ml, Po0.05). SVR increased after intralipid compared to the change after saline (0.6 ± 3.1 vs À2.7 ± 2.5 mm Hg.l.min À1 , Po0.01). L-NMMA reduced forearm blood flow less after intralipid compared to saline (mean reduction: 0.61±0.13 vs 1.10±0.28 ml min À1 100 ml À1 , Po0.05). Exercise diastolic blood pressure was higher after intralipid compared to after saline (68.0±4.6 vs 63.3±4.7 mm Hg, Po0.05). These results are consistent with an acute elevation of NEFA causing an increase in oxidative stress, decrease in availability of basal NO and increase in SVR at rest and during exercise. 
